肿瘤学中的血管靶向治疗
Vascular targeted therapies in oncology.
作者信息
Siemann Dietmar W, Horsman Michael R
机构信息
Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL, USA.
出版信息
Cell Tissue Res. 2009 Jan;335(1):241-8. doi: 10.1007/s00441-008-0646-0. Epub 2008 Aug 28.
Abstract
Neovascularization is intimately involved in tumor survival, progression, and spread, factors known to contribute significantly to treatment failures. Thus, strategies targeting the tumor blood vessel support network may offer not only unique therapeutic opportunities in their own right, but also novel means of enhancing the efficacies of conventional anticancer treatments. This article reviews one such therapeutic approach directed at the tumor blood vessel support network. Vascular disrupting therapies seek the destruction of the established neovasculature of actively growing tumors. The goal of these therapies is to cause a rapid and catastrophic shutdown in the vascular function of the tumor in order to arrest the blood flow and produce tumor cell death as a result of oxygen and nutrient deprivation and the build up of waste products.
摘要
新生血管形成与肿瘤的存活、进展和扩散密切相关，而这些因素是导致治疗失败的重要原因。因此，针对肿瘤血管支持网络的策略不仅本身可能提供独特的治疗机会，还可能成为增强传统抗癌治疗效果的新方法。本文综述了一种针对肿瘤血管支持网络的治疗方法。血管破坏疗法旨在破坏活跃生长肿瘤中已形成的新生血管。这些疗法的目标是使肿瘤的血管功能迅速发生灾难性的关闭，从而阻止血流，并由于氧气和营养物质的缺乏以及废物的积累导致肿瘤细胞死亡。
相似文献
1
Vascular targeted therapies in oncology.
Cell Tissue Res. 2009 Jan;335(1):241-8. doi: 10.1007/s00441-008-0646-0. Epub 2008 Aug 28.
2
Targeting the tumor vascular compartment to improve conventional cancer therapy.
Trends Pharmacol Sci. 2004 Oct;25(10):536-42. doi: 10.1016/j.tips.2004.08.008.
3
Tumor rim cells: From resistance to vascular targeting agents to complete tumor ablation.
Tumour Biol. 2017 Mar;39(3):1010428317691001. doi: 10.1177/1010428317691001.
4
Computer Simulations of the Tumor Vasculature: Applications to Interstitial Fluid Flow, Drug Delivery, and Oxygen Supply.
Adv Exp Med Biol. 2016;936:31-72. doi: 10.1007/978-3-319-42023-3_3.
5
Physical determinants of vascular network remodeling during tumor growth.
Eur Phys J E Soft Matter. 2010 Oct;33(2):149-63. doi: 10.1140/epje/i2010-10611-6. Epub 2010 Jul 6.
6
Vessel abnormalization: another hallmark of cancer? Molecular mechanisms and therapeutic implications.
Curr Opin Genet Dev. 2011 Feb;21(1):73-9. doi: 10.1016/j.gde.2010.10.008. Epub 2010 Nov 22.
7
Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
Prog Biophys Mol Biol. 2013 Nov;113(2):333-54. doi: 10.1016/j.pbiomolbio.2013.10.001. Epub 2013 Oct 15.
8
Tumor angiogenesis: a potential target in cancer control by phytochemicals.
Curr Cancer Drug Targets. 2003 Jun;3(3):205-17. doi: 10.2174/1568009033481985.
9
Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases.
Nat Rev Drug Discov. 2011 Jun;10(6):417-27. doi: 10.1038/nrd3455.
10
Angiogenesis inhibitors. Drug selectivity and target specificity.
Curr Pharm Des. 2007;13(27):2795-809. doi: 10.2174/138161207781757033.
引用本文的文献
1
Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization.
ACS Med Chem Lett. 2025 May 26;16(6):1098-1107. doi: 10.1021/acsmedchemlett.5c00129. eCollection 2025 Jun 12.
2
Vascularized tumor on a microfluidic chip to study mechanisms promoting tumor neovascularization and vascular targeted therapies.
Theranostics. 2025 Jan 1;15(3):766-783. doi: 10.7150/thno.95334. eCollection 2025.
3
Targeting the Tumor Vascular Supply to Enhance Radiation Therapy Administered in Single or Clinically Relevant Fractionated Schedules.
Int J Mol Sci. 2024 Jul 24;25(15):8078. doi: 10.3390/ijms25158078.
4
Targeting circulating tumor cells to prevent metastases.
Hum Cell. 2024 Jan;37(1):101-120. doi: 10.1007/s13577-023-00992-6. Epub 2023 Oct 24.
5
Synthesis of a boron-containing amidoxime reagent and its application to synthesize functionalized oxadiazole and quinazolinone derivatives.
Tetrahedron Lett. 2022 Mar 2;92. doi: 10.1016/j.tetlet.2022.153657. Epub 2022 Jan 25.
6
3D-Cultured Vascular-Like Networks Enable Validation of Vascular Disruption Properties of Drugs .
Front Bioeng Biotechnol. 2022 Jun 13;10:888492. doi: 10.3389/fbioe.2022.888492. eCollection 2022.
7
Noninvasive imaging of tumor hypoxia after nanoparticle-mediated tumor vascular disruption.
PLoS One. 2020 Jul 24;15(7):e0236245. doi: 10.1371/journal.pone.0236245. eCollection 2020.
8
High glucose concentration produces a short-term increase in pERK1/2 and p85 proteins, having a direct angiogenetic effect by an action similar to VEGF.
Acta Diabetol. 2020 Aug;57(8):947-958. doi: 10.1007/s00592-020-01501-z. Epub 2020 Mar 4.
9
Treatment of Hepatocellular Carcinoma by Intratumoral Injection of I-AA98 mAb and Its Efficacy Assessments by Molecular Imaging.
Front Bioeng Biotechnol. 2019 Nov 14;7:319. doi: 10.3389/fbioe.2019.00319. eCollection 2019.
10
Selective Priming of Tumor Blood Vessels by Radiation Therapy Enhances Nanodrug Delivery.
Sci Rep. 2019 Nov 1;9(1):15844. doi: 10.1038/s41598-019-50538-w.
本文引用的文献
1
An update on the clinical development of drugs to disable tumor vasculature.
Expert Opin Drug Discov. 2007 Oct;2(10):1357-67. doi: 10.1517/17460441.2.10.1357.
2
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies.
Cancer Res. 2006 Dec 15;66(24):11520-39. doi: 10.1158/0008-5472.CAN-06-2848.
3
On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent.
J Clin Oncol. 2006 Aug 20;24(24):4040; author reply 4040-1. doi: 10.1200/JCO.2006.07.1175.
4
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity.
Clin Cancer Res. 2006 Jul 1;12(13):4090-4. doi: 10.1158/1078-0432.CCR-06-0163.
5
Current development status of small-molecule vascular disrupting agents.
Curr Opin Investig Drugs. 2006 Jun;7(6):522-8.
6
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent.
Clin Cancer Res. 2006 Mar 15;12(6):1776-84. doi: 10.1158/1078-0432.CCR-05-1939.
7
Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling.
J Clin Invest. 2005 Nov;115(11):2992-3006. doi: 10.1172/JCI24586. Epub 2005 Oct 13.
8
Disrupting tumour blood vessels.
Nat Rev Cancer. 2005 Jun;5(6):423-35. doi: 10.1038/nrc1628.
9
Differentiation and definition of vascular-targeted therapies.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):416-20.
10
Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumors.
Int J Radiat Oncol Biol Phys. 2004 Nov 15;60(4):1233-40. doi: 10.1016/j.ijrobp.2004.08.002.
Zotero 插件